
Cost and insurance coverage, not efficacy alone, ultimately determined this patient's treatment course. His account of near out-of-pocket biologic spending underscores why access considerations belong at the center of shared decision-making.

Cost and insurance coverage, not efficacy alone, ultimately determined this patient's treatment course. His account of near out-of-pocket biologic spending underscores why access considerations belong at the center of shared decision-making.

An 83-year-old patient's three-decade psoriasis journey, shaped by a comorbid MGUS diagnosis and a hospitalization that upended his treatment plan, reveals how much medical history can redirect a therapy path.

Scalp and nail involvement remain among psoriasis's most difficult-to-treat presentations. The panel reviews site-specific efficacy data and outlines a practical approach to monitoring safety and managing breakthrough symptoms.

Deciding whether to retrain self-injection technique or transition to office-based administration hinges on identifying the true barrier, while high-impact sites like the scalp and nails raise the stakes considerably.

A biologic-experienced night-shift worker with limited response to her current therapy raises a critical diagnostic question: is this true treatment failure, or an adherence problem hiding behind a demanding schedule?

Persistence and adherence, not efficacy claims alone, distinguish IL-23 biologics in practice. Real-world claims data reveal how administration setting and dosing interval shape whether older patients stay on therapy.

Injection anxiety, transportation barriers, and Medicare Part B eligibility converge in this case to make office-administered biologic therapy not a fallback, but often the most realistic path to sustained treatment.

Age alone should not dictate biologic hesitancy. The panel challenges the assumption that systemic therapies are inherently riskier in older adults, pointing to safety data and the realities of polypharmacy.

An independence-minded 72-year-old with hand arthritis and missed oral doses forces a reassessment of what a workable psoriasis regimen looks like once dexterity and daily routine become limiting factors.

Speed of onset and long-term durability are often treated as competing priorities. Dr. Armstrong argues they are not mutually exclusive, and details how cardiometabolic comorbidities and how emerging incretin-therapy data may extend treatment options beyond skin clearance alone.

With more biologic classes available than ever, selecting a first-line agent for a treatment-naive patient increasingly depends on comorbidity screening, lifestyle fit, and realistic expectations rather than efficacy data alone.

A systemic-naive roofer with extensive plaque psoriasis and cardiometabolic risk illustrates why compliance history, not just disease severity, should shape the first conversation about moving beyond topical therapy.

As biologics multiply, the boundary between topical failure and systemic eligibility remains contested. Dr. Armstrong outlines the severity thresholds, comorbidities, and quality-of-life factors that most reliably justify escalating plaque psoriasis therapy.